Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in ...

A cumulative $5.67 billion flowed into Indian healthcare firms — from traditional hospitals to medical robotics startups and ...

Meanwhile, WuXi Vaccines, a subsidiary of WuXi Biologics, says it will sell a vaccine facility in Dundalk, Ireland, to the US drugmaker Merck & Co. for $521 million. WuXi Biologics says the sale ...

Dr. Michael Har-Noy, Founder and Chief Medical Officer of Mirror Biologics stated: “We are pleased to enter into this clinical collaboration with Merck KGaA, Darmstadt, Germany, evaluating the ...

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co. for approximately USD 500 million. The decision comes ahead of potential U.S ...

(Borrell, 1/7) Reuters: China's WuXi Biologics To Sell Irish Vaccine Facility To Merck As US Curbs Loom China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S.

Dr. Michael Har-Noy, Founder and Chief Medical Officer of Mirror Biologics stated:“We are pleased to enter into this clinical collaboration with Merck KGaA, Darmstadt, Germany, evaluating the ...